Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics has two commercial products, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, which is partnered with Bausch Health Companies, Inc.; and AZEDRA, for the treatment of unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy.
|Headquarters||New York, New York|
|Number of employees||51-200 employees|
Top 5 Recent Tweets
|March 31, 2023||urotoday||#TumorBoard reviewing the use of PSMA PET in #ProstateCancer - Gleason 3+3=6 GG 1, PALB2 mutations. @HJacene… https://t.co/BJFJ75rbGp|
|March 30, 2023||urotoday||#TumorBoard Reviewing the Use of PSMA PET in #ProstateCancer Gleason 4+4=8 GG 4, PI-RADS 5 Lesion, Possible Seminal… https://t.co/Mkr6UuP7Nq|